GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2014 · 1 min read
In brief
In brief
This preclinical study demonstrates that GANT-61, a GLI1/2 inhibitor, reduces growth of both embryonal and alveolar rhabdomyosarcoma xenografts by approximately 50% through disruption of Shh/AKT-mTOR signaling and cell cycle arrest. The therapeutic effect is enhanced when combined with standard chemotherapy agents like temsirolimus or vincristine.
Written by the GCMD Library team from the article.
Statements in this article
Rhabdomyosarcoma in patients with recurrent and metastatic disease have no successful treatment.
Some embryonal rhabdomyosarcoma but not other sub-types are driven by sonic hedgehog signaling pathway.
Smoothened inhibitors are not highly effective in animals for treating rhabdomyosarcoma.
GLI1 and/or GLI2 are over-expressed in the majority of rhabdomyosarcoma cells.
GANT-61 dampens the proliferation of both embryonal and alveolar rhabdomyosarcoma cells-derived xenograft tumors.
About 50% tumor growth inhibition occurs in mice receiving GANT-61 treatment compared to vehicle-treated control.
GANT-61 proliferation inhibition is associated with slowing of cell cycle progression mediated by reduced expression of cyclins D1/2/3 and E and concomitant induction of p21.
GANT-61 reduces expression of GLI1/2 in rhabdomyosarcoma cells.
GANT-61 significantly diminishes AKT/mTOR signaling in rhabdomyosarcoma.
The therapeutic action of GANT-61 is significantly augmented when combined with temsirolimus or vincristine.
Reduced expression of proteins driving epithelial mesenchymal transition characterizes residual tumors after GANT-61 treatment.